Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bentivoglio...LinkedIn profile, Event Cardio Group......
SUIP...probable RM with Event Cardio Group.....
A Google search of the new phone number listed on yesterday's 8-K shows there is a connection to Event Cardio Group (a start-up medical device/software/telemedicine company based in Canada). I am assuming the RM will likely be done with this company.....
John Bentivoglio
CEO and President, ECG Inc.
United States|Medical Devices
CEO and President
Event Cardio Group Inc.
September 2012 – Present (1 year 11 months)
John Bentivoglio, is focused on his newest role as President, CEO and Main Principal of Event Cardio Group. For John, being the Main Principle of a Public Company, comes after many successful years of assisting, and being a partner.
CardioNow
Played a key role in development of “NowCardio”, a modern cardio-monitoring product, over the past two years. Actively sought out fund raising, while developing strategies for entering the public market.
BFNH(.055)...shell, new business direction.....
36M shares outstanding
$2M market cap
BFNH(.0255)...established a position.....
Picked up a few shares of BFNH at 3 cents for a speculative position, just in case any OTC or SEC filings appear and trigger some buying interest.
Following the resignation of officers, appointment of a new CEO and reinstatement of the stock in March, I am assuming that BFNH is currently in shell status. But it certainly appears to me that some corporate event/action may be approaching at some point "relatively soon".
It has gone largely unnoticed, but on July 29 BFNH's corporate officer list on Nevada was updated to include Richard Kaiser as Secretary. It would seem highly unusual for a shell to hire/appoint Kaiser (Yes International, investor relations firm) as Secretary unless there are plans to make filings and/or press releases.......
SUIP(.045)...shell, change in control....
6.9M shares outstanding
5.5M float
$310K market cap
I continue to hold a full/large position in the SUIP shell. The recent change in control should advance SUIP closer to making a reverse merger transaction.
The usual shell/RM risks apply here: any excessive or abnormal pre/post-RM dilution, any unattractive financings, etc. But if the new/current CEO handles things reasonably well, the potential for nice upside exists here, IMO.
My guess/speculation over on the SUIP message board is that the RM target for SUIP is a medical device company (ambulatory medical devices) in Canada (Event Cardio Group). According to that particular company's website and the below article, Event Cardio Group will be applying for marketing approval for both Canada and the United States during 2015. Engineering design and development of its product(s) is being done by Contex Engineering Canada.
http://www.eventcardiogroup.com/Products
http://www.niagarahealthday.com/presenter-nicholas-bozza/
jasonak...regarding MRDH.....
The 13Mar PR seems a weak to me...you must have something else here for your taking a large position?
MRDH(.025)...accumulated a position.....
I've accumulated a good-sized position in MRDH (primarily involved in medical/health/insurance management). This is a high-risk investment for a number/variety of reasons, but my hunch/guess is something will trigger a significant increase in the share price at some point in the next 12 months or so.
I think the March 13 press release was the first one MRDH had issued in nearly 6 years. About one week ago, that March PR was placed in the "press release" section(s) of the MRDH website(s). Up until that point the website(s) had been relatively static during the time that I have been following/accumulating the stock. So the possibility that MRDH might increase its level of investor relations activity and/or resume its filings (SEC or otherwise) makes this situation look pretty interesting to me.
MRDH's last periodic report was filed in 2006, and its business activity at that time was primarily limited to medical/health management in the state of California. MRDH's primary business focus since 2012 appears to be its nation-wide Accountable Care Organization.....
BLUE BELL, Pa. & HAWTHORNE, Calif., Mar 13, 2014 (BUSINESS WIRE) -- Halfpenny Technologies was selected by Meridian Health Systems ACO Corporation, a wholly owned subsidiary of Meridian Holdings, Inc. (symbol:MRDH), as their exclusive partner for the management and exchange of laboratory data. This partnership with Halfpenny Technologies creates true interoperability between Meridian Health Systems ACO, a nationwide Accountable Care and Independent Medical Review Organization, with over 700 contracted participants, providers and suppliers located in 50 states, including the District of Columbia. Halfpenny Technologies will provide a secure and scalable interface engine that will allow for the exchange of aggregated and normalized lab data between the ACO’s referring physicians, providers and health insurance partners.
SUIP...probable RM with Event Cardio Group.....
A Google search of the new phone number listed on yesterday's 8-K shows there is a connection to Event Cardio Group (a start-up medical device/software/telemedicine company based in Canada). I am assuming the RM will likely be done with this company.....
For additional information,
please contact
Mr. John Bentivoglio Sr VP
Event Cardio Group Inc.
Email: johnb@eventcardiogroup.com
Direct U.S. Line: 561-271-7157 or Direct Canadian Line: 289-407-4377
-Or-
Nicholas Bozza President
Event Cardio Group Inc.
Email: nickb@eventcardiogroup.com
Canadian Direct Canadian Line: (905) 650 4022
John Bentivoglio VP Secretary and Treasury, is a senior partner with Profit Consultants, Inc. an international consulting firm with offices in Houston, Texas, Montreal, Canada and London, UK. Mr. Bentivoglio’s accomplishments include mergers and acquisitions of publicly traded companies together with General Management roles with global restaurant chains and treasury management. Mr. Bentivoglio has an education in Business Administration.
Nicholas (Nick) Bozza CEO and founder of ECGI has ten years’ experience in the cardiology therapeutic area and is the President of CAII. Mr. Bozza has gained expert-level knowledge of the cardiac diagnostics market through the development of CAII and his key relationships with payers, physicians and patients. Mr. Bozza holds a Bachelor of Arts with a major in Marketing and Economics and a Bachelor of Arts in Health Sciences.
VODG(.133)..revenue acceleration, near-term profitability.....
I'm fully expecting to see some nice upward movement (either sustained or tradeable spikes/swings) in the stock at some point in calendar 2014 or the first quarter of 2015. Although the numbers might be relatively small, VODG has been experiencing a trend of accelerating revenue and the company appears to be fully intent on posting bottom-line profits by at least Q4 (August-October 2014).
VODG has been significantly increasing the breadth of its product offerings, as well as making changes to its overall business focus/approach. You can often get advance information on VODG developments by monitoring the various social media websites associated with Neuromics and Pete Shuster (VODG's product distributor and Director).
Excerpts from the last two press releases issued by VODG.....
1)
Golden, Colorado—May 6, 2014—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced completion of its second fiscal quarter. Revenues continue to show strong growth and the Company projects near-term attainment of profitable operations. Total revenues increased three-fold (300%) in the first six months of 2014 compared to the same period in 2013 from increased product sales and revenues from contract research services. Our products include adult stem cells and several formulations of cell culture media for stem cell growth and differentiation. Our products have competitive advantages including out-performance of competitor’s products in several different aspects. We have recently added new products including cell lines and stem cell media products for culture of canine and equine stem cells. Revenue from products rose by 70% over the first 6 months of 2013.
Dr. Jim Musick, Vitro Biopharma’s President & CEO said, “We are very pleased to announce continued revenue growth during the first six months of 2014. This is a direct reflection of our increased collaboration with Neuromics, Inc. At the end of December we decided to defer our merger and focus instead on growing the revenue and earnings of Vitro Biopharma to profitability. This would result in positive earnings for the subsequent merger of the two companies. That plan has been operational since then and I am pleased to say that this is working quite well. We anticipate continued growth of revenues throughout 2014 and project profitable operations at the end of 2014. In addition we anticipate the establishment of platforms to accelerate revenues & earnings growth substantially through our regenerative medicine and drug discovery/development initiatives. Vitro Biopharma has relatively limited number of common shares issued and outstanding, approximately 20 million that is very modest for comparable companies. With our ability to generate earnings and rapid earnings growth, we anticipate strong earnings per share growth as we go forward which is one of the fundamental aspects of Vitro Biopharma. We have very actively attempted to maintain a favorable capital structure for the company.”
Pete Shuster, a Director of Vitro Biopharma and the CEO & founder of Neuromics said “The excellent work being done by Jim and his team has opened up two new and predictable revenue sources for Vitro Biopharma. First, the assays developed to test the potency of our stem cell activating agents are excellent for stem cell based drug discovery. These assays can be used to test small molecules/compounds, for cell-based drug delivery and toxicity studies. We have a wealth of data available to support our value proposition. We are in the process of developing a plan to make these assays available to biopharma companies in a way that best fits their requirements. Secondly, we have started generating revenue by providing these tested activators to select clients in Europe. Initial therapeutic value is encouraging pending more testing after 3-6 months of treatment. We have plans to ramp up our stem cell activating products rapidly pending results. We anticipate these developments will enable Vitro Biopharma become cash flow positive in Q3 and consistently profitable starting in Q4, 2014.
Management change...today's press release.....
Things should get a bit more interesting from a corporate/business activity standpoint now that Sam Gaer has taken the CEO position at RDFY again.
Today's press release......
Redify Group Announces Management Changes Company Moves Headquarters Back to New York City
New York, NY, May 31, 2014 --(PR.com)-- Redify Group, Inc. (OTCQB:RDFY) (“Redify”) a leading technology and mobile app development company, today announced the addition of two highly successful and talented members to its management team. Samuel Gaer, the company’s founder, was re-appointed Chief Executive Officer and Director. The company also announced that David Greenberg was elected to its Board of Directors. The company is also happy to announce it will be returning to New York as its headquarters.
Mr. Gaer will replace S. Emerson Lybbert, who will remain with the company as Chairman of the Board and Chief Financial Officer. Mr. Gaer has vast experience in enterprise technology and business development. He was the chief information officer and executive vice president of NYMEX Holdings Inc. where he was twice recognized by CIO Magazine as one of the top 100 CIO’s in the nation. Mr. Gaer was the chief information officer of FINRA where he oversaw all technology and transparency services of the security industry’s regulator. Mr. Gaer is the creator of Redify’s SportsCast line of Personal Sports Broadcasting(sm) apps for Apple’s iPhone.
Mr. Greenberg served on the New York Mercantile Exchange Board of Directors from 2000 to 2007 and during that time, served one term on the New York Mercantile Exchange Executive Committee. He has served as President of Sterling Commodities, Vice President of the Commodity Futures Brokers and Traders Association and Board Member of the Futures and Options for Kids Foundation. He is currently President of Greenberg Capital, LLC. Mr. Greenberg is a frequent commentator on CNBC and Fox Business News.
“I’m excited to be back at Redify and look forward to creating value for our shareholders,” said Sam Gaer. “We are getting right to work on new versions of our SportsCast apps and exploring new opportunities for the company. I’m elated to bring David on as a board member and look forward to collaborating with him.”
“Redify is extremely excited to welcome Mr. Gaer back and bring Mr. Greenberg on board,” said Chairman Lybbert. “They are uniquely positioned to move the company forward as we develop our suite of sports applications. Together, we will further our plans to acquire technology and intellectual property, as well as bringing other profitable opportunities under the Redify umbrella.”
Contact Information
Redify Group, Inc.
S. Emerson Lybbert or Sam Gaer
212.658.0779
Contact
813.503.7584
VKIN(.42)...investor relations firm hired.....
Added a few shares to my position today and Friday, just in case both an anticipated management change and private placement (at a nearly 100% premium) are completed and confirmed sometime in the near future (hopefully within the next week or two). High risk situation because the company allowed Asher Enterprise to convert much of its debt, but there have been periods of very unusual/strong buying interest in this stock ever since a change-in-control agreement was announced back in March.
The quarterly report filed last week mentioned that the change-in-control was expected to be completed on May 15 (Thursday). The last press release issued by VKIN stated that the private placement was expected to be completed sometime around May 23 (this Friday)......
RDFY...website online, lead generation platform.....
With the recent financing(s), the fully-diluted share count is probably somewhere in the 4-4.5M area. Insiders (Sam/Marnie Gaer)continue to provide financial support to the company at 10 cents.
The RDFY website came back online a few weeks ago. Although the site is still not fully functional/operational, there were a few changes/updates made.
Interesting to note the new verbiage that now exists in the "lead generation platform" section of the website......
Redify will soon put its new Lead Generation platform into production. Designed to with advanced cloud-based data-mining capabilites, we believe that this platform will very quickly be at the forefront of online lead generation and afiiliate referrals.
Redify is teaming up with industry experts to create this platform and has already signed up with the largest affiliate lead generation network in the alternative lending area.
Redify will focus on emerging marketplace trends and create attractive and compelling lead generation campaigns to drive traffic to our publishers.
VKIN(.26)...increased my position....
20M shares outstanding
Added a few shares to my position today and Friday, just in case both an anticipated management change and private placement (at a nearly 100% premium) are completed and confirmed sometime in the near future (hopefully within the next week or two). High risk situation because the company allowed Asher Enterprise to convert much of its debt, but there have been periods of very unusual/strong buying interest in this stock ever since a change-in-control agreement was announced back in March.
The quarterly report filed last week mentioned that the change-in-control was expected to be completed on May 15 (Thursday). The last press release issued by VKIN stated that the private placement was expected to be completed sometime around May 23 (this Friday)......
Viking Investments Group, Inc. (“Viking”) (OTC: VKIN) is pleased to announce that it intends to complete a private placement for gross proceeds of $2,000,000 (the “Financing”). These funds will be raised by the issuance of 4,000,000 Units (the “Units”) at a price of $0.50 per Unit (currently being a premium to the Company’s market price), each Unit consisting of one common share and one share purchase warrant (the “Warrants”), each whole Warrant entitling the holder thereof to purchase one additional common share, exercisable for a period of one (1) year from the date of issuance at a price of $0.75 per share. The Units will be issued to more than one investor.
Proceeds raised from the Financing will be used to purchase an equity interest in one or more publicly-traded companies actively engaged in the commercial production of oil and gas, and for general working capital.
The Financing is expected to close on or about May 23, 2014.
MSHS(.51)...shell option agreement extended.....
1.19M shares outstanding
600K float
$290+K debt
Accumulated some shares of the MSHS shell during 2013 around the 20-cent area.
On May 16, 2013, The Globe Resources Group, LLC (Gerald O'Shaughnessy) acquired a 12-month option to purchase 38.5M shares of MSHS. With the 8-k filing this morning, that option agreement has been extended an additional 30 days......
On May 15, 2014, Minn Shares, Inc. (the “Company”) and The Globe Resources Group, LLC (the “Purchaser”) entered into a letter agreement (the “Extension Agreement”), pursuant to which the parties agreed to extend the 12 month option period described in that certain Option Agreement, dated May 16, 2013, by and between the Company and the Purchaser (the “Option Agreement”) pursuant to which the Purchaser acquired an option to purchase 38,520,252 shares (approximately 97%) of the Company’s common stock for an additional 30 days. In exchange for the 30 day extension, the Purchaser agreed to pay (i) $15,000 for a current outstanding payable of the Company and (ii) additional legal and administrative expenses associated with the preparation of the Extension Agreement and the filing of this Current Report on Form 8-K with the Securities and Exchange Commission.
MRDH...accumulated a position.....
Finished accumulating a position in MRDH. High-risk type of investment here until the CEO updates the financials, but the risk/reward around this 2-3 cent area looks pretty interesting to me. If the outstanding share count continues to be around that 20M area, and that recent press release is a harbinger of increased investor relations activity, I am anticipating some significant upside movement sometime in this calendar year.
At the time the company stopped filing, the financials looked relatively "clean" with positive shareholder equity, so my hunch/guess is that there will not be anything overly negative/damaging if they start filing again. The CEO/CFO/company got in trouble with the SEC back in 2009 for overstating its earnings (improperly recognized a $30+M lawsuit judgment, which they knew was likely uncollectible).
One thing I will be interested to see is if the company makes any acquisitions or expansions into other areas of business outside its current focus on healthcare management. It is interesting to note that MRDH CEO Anthony C. Dike also is the President/CEO and controlling shareholder of Meridian Health Systems, P.C., which is a privately-held cardiovascular device company that has licensed medical technology from NASA......
Endothelium-Preserving Microwave Treatment for Atherosclerosis
The Endothelium-
Preserving Microwave
Treatment for
Atherosclerosis was
first developed and
patented by engineers
at NASA’s Johnson
Space Center (JSC).
The apparatus and
method enable the
repair of diseased coronary arteries during cardiac
catheterization by delivering microwave energy
to precise arterial locations to selectively target
and heat atherosclerotic lesions. The treatment
preserves the most delicate endothelial cell layer,
which is especially important for preventing
restenosis due to thrombotic, inflammatory, and
proliferative responses that complicate current
treatment procedures.
In the 1990s, JSC engineers were investigating
the use of millimeter waves to collect images
of the human body. They rented an expensive
experimental imaging system, but determined
early on that the millimeter wave technology
was not going to be useful for the original intent.
They brainstormed other uses and theorized that
it could be adapted for use in a miniaturized,
directional antenna attached to a catheter.
Inserted into a diseased artery, the millimeter
wave transmissions could penetrate the artery
wall and destroy atherosclerotic lesions without
damaging healthy tissue and cells. The validity
of this concept was subsequently confirmed by
a local physician. They patented the apparatus
and method in December 2002.
JSC met with Meridian Health Systems, P.C.
of Los Angeles, California, to discuss the
technology’s feasibility and effectiveness. In
July 2011 the two organizations signed a Space
Act Agreement (SAA) to conduct feasibility
studies and further develop the technology
collaboratively. After a successful technology
demonstration in November 2011, NASA
licensed the technology to Meridian through a
partially exclusive patent license agreement.
JSC and Meridian are currently negotiating a
second, novel “umbrella SAA” that will include
separate annexes for different technology areas
to further speed testing and development.
Meridian intends to market the technology as the
Endothelium Preserving Microwave Treatment for
Atherosclerosis (EPMTA™) Angioplasty Device
for the nonsurgical repair of diseased coronary
arteries. The effort at Meridian is championed
by Dr. Anthony C. Dike, President and CEO.
“Cardiovascular disease has been the leading
cause of death in the United States every year
since 1918,” Dike said. “My company believes that
the need has never been greater for a minimal
or noninvasive, low-cost tool such as this for the
management of individuals at risk for coronary
artery disease.”
Doubloon...source of my content, entire story.....
Well it's not my place to change your mind about management and how they operate, you obviously take much of your content from message boards so I would suggest you call John directly and ask him, until you do that you do not have the entire story. His cell phone number is 410-236-8200.
Doubloon...CEO, financing, etc.....
Anyone that blames a mining company or it's management should not be in the investing arena, I am so sick of these cry babies. I am willing to ride it out, I made the decisions and I will live by them.
One thing with this company, it has over $46 million in proven reserves and a market cap of $1.4 million, it is the attitude of the investing public that needs a kick in the pants.
On February 15, 2014, the Company executed a term sheet with a third party in which the third party shall invest a gross sum of $1,000,000 in exchange for a 50% interest in the Company. The 50% interest shall be delivered in the form of the Company’s common stock. The Company agrees to pay 15%, or $150,000, in fees associated with the funding, and issue 7.5% of the Company’s common stock to the third party for the placement of the aforementioned funds. In addition, the third party will have the right to appoint two members to the Company’s Board of Directors.
On February 18, 2014, the Company issued a convertible promissory note to a third party in the amount of $47,500. The note accrues interest at the rate of 8% per annum and has a maturity date of November 20, 2014. The note is convertible after 180 days from the date of issuance at 58% of the average lowest three-day trading price of common stock during the 10 days preceding the date of conversion.
GNPG...Nevada reinstatement, new website.....
Finished accumulating a position in GNPG. I'm anticipating a significant increase in the share price from around this 2-cent area sometime in the next 6-12 months. The $300K investment from outside investors appears to have been done at .023/shr, so the risk/reward around the current price looks reasonably good to me (see post below).
Nevada reinstatement was done about two weeks ago.....
http://nvsos.gov/sosentitysearch/corpActions.aspx?lx8nvq=as2xw4brgMwVo5nFKBdk6g%253d%253d&CorpName=GREEN+PLANET+GROUP%2c+INC.
The new website for GNPG started coming online about a week ago....
http://greenplanetgroup.com/
Obviously, the possibility that GNPG's food growing system might eventually be applied to the marijuana sector probably makes it well worth having a few shares at current prices.
One thing I find somewhat interesting is they have noted in both the press release and the website text that this system will also be applied to the production of animal feed. Most contained/factory growing systems are generally focused on human food production, so this aspect of GNPG seems to set it apart from many of the other companies in this space. Text regarding the food growing system, from the "companies" section of the website.....
Healing the Earth, Inc., a development stage subsidiary, is developing a revolutionary “fast track” growing system that will be capable of growing vast amounts of fresh, organic food in cities (at point of consumption) thereby reducing transportation costs, reducing waste while improving both the quantity and quality of food. Matching food produced to local demand (food on demand) insures that all of the food produced will be consumed. This revolutionary growing system will be applied to foods for human consumption as well as agricultural application in the production of animal feed. Healing the Earth, Inc. has received funding to build a “Proof of Concept” installation in Congress, Arizona. As of March, 2014, engineering is under way and construction will begin soon. It is anticipated that the Congress installation will begin production in September, 2014.
thecrusher2011...Nevada filings, debt.....
I am perplexed as well. There is no convertible debt in the 10-Q. No registered shares in Nevada, no officers listed, yet they are still going through the expense of staying current with the SEC.
http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=KafWRum0DUH0LMoRRmH9pA%253d%253d&nt7=0
http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=KafWRum0DUH0LMoRRmH9pA%253d%253d&nt7=0
What gives?
On March 27, 2008, our board of directors and the majority holders of the Company’s capital stock jointly approved amendments to our Articles of Incorporation by written consent to change its name from “Sunrise Mining Corporation” to “Sunrise Holdings Limited” because the operations of the Company will be more diversified and expanded in the future and therefore a new corporate name is appropriate.
I did notice that most of the debts from the last 10-k are not on the newer 10-Q. How did the company pay those back?
GNPG(.02)...established a position.....
Picked up shares of GNPG last week for a high-risk, speculative position. The 1-2 cent area looks like a reasonable range for entry/accumulation.
Based on the last two press releases regarding its food growing system, it appears the $300K third-party investment in GNPG last week was done at a premium to the then-market price of around one cent. The stock was probably still in the sub-penny level when this deal was being negotiated.
The investors receive 8M shares for the $300K investment, and 5M shares for use of the property/facilities where the growing system will be established. The cost basis for the investors is more than .023 per share.
Maverick Asset...2013 financial agreement....
One piece of information that started showing up on scans a couple months or so ago was a financial agreement the company entered into with Maverick Asset Management back in May 2013. This news never appeared on the company website.
As best as I can determine, Maverick is part of a large private equity, investment/business management firm in China. According to the agreement, Maverick is/was to introduce overseas investors to the company.
Somewhat interesting to note that DION appointed those two new management/director people (post #84) about four months after this meeting/agreement with Maverick, A couple photos of the signing ceremony are included in the news item below......
May 15, 2013, Maverick (Global) Asset Management Limited ("Maverick Assets") and Shangrao Baihuazhou Industrial Co., Ltd. (referred to as "Baihuazhou") overseas financing agreement signing ceremony was held at Beijing Olympic letter headquarters. Beijing Olympic letter Holding Chairman Mr. Wang Ping, Mr. Zhao Tong, president of Maverick assets, such as Miss Li Xiaoling Baihuazhou a pedestrian chairman attended the signing ceremony.
Maverick assets as a global asset management company, will introduce strategic investors to invest overseas institutional Baihuazhou. As Maverick assets, one of the nation's largest institutional investors and leading companies Baihuazhou landscaping, there is a strong complementarity of both extensive business cooperation in space as well as in business, the signing of this agreement will help to promote the bilateral strategic partnership further development.
http://translate.googleusercontent.com/translate_c?depth=1&hl=en&prev=/search%3Fq%3D%2522http://www.auxin.cn%2522%26num%3D30%26safe%3Doff&rurl=translate.google.com&sl=zh-CN&u=http://www.auxin.cn/index.php%3Fm%3Dcontent%26c%3Dindex%26a%3Dshow%26catid%3D20%26id%3D167&usg=ALkJrhiM-YBsIYdLTnxNTVXGoOafdFp5Lg
Vitropin, wound care, revenue updates.....
Probably a good chance at seeing some type of significant third-party promotion and/or a momentum-assisted move in the share price at some point in calendar 2014. Based on the latest press release and the 10-K filing, the level of corporate/business activity appears to be increasing, and it might start attracting more interest in the coming months.
Vitropin: Although the two parties have decided to keep the Vitropin license agreement active for the time being, it doesn't look like VODG will extract much value from this asset unless an existing player in the space expresses interest in the drug/technology......
During 2011, we completed out-licensing of our patented technology related to FSH manufacture as described elsewhere in this Report. We have a well-established business relationship with the licensee through numerous prior business activities and now also provide the licensee with assistance in sourcing necessary raw materials, distribution of finished product and options to advanced stem-cell based methods for FSH production. The anticipated manufacturing contract with the Contract Manufacturing Organization was not completed in 2013 and there appear to be obstacles to commercialization of Vitropin™. Since many of the primary patents for proprietary FSH drugs have now expired, there a several generic products being introduced to the global market. Many competitors are gaining entry through highly competitive pricing and this is diminishing return on investment capital discouraging further investment.
Wound care product(s): It does appear that some type of joint product development between VODG and James Posillico in the wound care product area may be progressing toward becoming something "official". This is now the first time that VODG has addressed/acknowledged this particular product development in an SEC filing......
However, as described elsewhere, Item 6 of this Report, we are pursuing additional collaboration with our FSH licensee to jointly develop products targeting enhanced wound healing based on novel polymers and known wound healing properties of stem cells.
While it appears that commercialization opportunities for therapeutic FSH are diminishing due to predatory pricing strategies by numerous competitors (See Part I, Item 1), we are developing further opportunities for joint product development with our current FSH patent licensee, Dr. James Posillico. MSCs are known to promote wound healing and through strategic combination of proprietary polymer technology, we are discussing additional collaboration to combine our proprietary stem cell technology and know-how to develop unique wound healing products.
2014 Q1 revenue: Looks like the first quarter revenue will come in over 26K, more than the previous three quarters combined. That would also represent four consecutive quarters of revenue growth. It should be interesting to see if there will be a sequential increase in the second quarter. VODG's expansion into CRO services should provide a more consistently higher level of revenue going forward.....
Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced that its revenues increased substantially (78%, unaudited) in its first 2014 fiscal quarter due to its growing and expanding business relationship with Neuromics, Inc. Vitro Biopharma has now commercialized bio-analytical services as the initial stage in its expansion as a Contract Research Organization (CRO). The services now available include select and customized biomarker panel analysis providing customers quantitative levels of multiple biological molecules within various biological samples. The new business involves analysis of human serum samples collected from patients within a network of clinical treatment centers throughout central Europe. Our partner for these services is Joseph Smarta, Ph.D., a renowned immunologist who has orchestrated treatment of many patients suffering from a variety of diseases. While the analyses are for research purposes only, serial analysis of patients are provided to monitor status and indicate therapeutic effectiveness.
Joseph Smarda: Below is an interview Smarda did last week. It primarily focuses on his work with sports figures......
http://www.ibestof.cz/medicina/rndr.-joseph-smarda-bsc.-%E2%80%93-immunologist-biochemist-.html
TEEE(.074)...accumulated more shares today.....
5.85M shares outstanding
$526K market cap
A 1:14.62 reverse split is expected in the next week or so.
Picked up a few more shares of the TEEE shell. All significant debt/liabilities appear to have been resolved now, with conversions into common stock generally in the 4-7 cent area (including shares issued to the shell's CEO, who will remain a Director with the new company).
The valuation of the shell under the 10-cent area still seems reasonable to me prior to the entry into a RM deal. Although there is quite a bit of risk involved here since I don't know what the financials and balance sheet of the RM target(s) look like, or what the final share structure will look like, I think there is a chance this stock might become an interesting low float and/or momentum play at some point after the reverse merger. Following the reverse split and the first part of the RM transaction, it appears that the tradeable float on this stock could be as low as 250K for awhile.
Office Manager to perform office management duties as well as Executive Assistant duties to a medical device sales company. The company is currently experiencing rapid growth and is in the midst of going public. Skill set must include understanding of hospital/ASC billing and or codes, coordination with manufacturers for product supply, coordination for executive team's calendar and travel. filing, account maintenance and customer service work
Items from the December 12 8-K.....
I'm still expecting to see higher prices here once the press releases and/or promotional activities start. I was looking to get a minimum of a 5-bagger on this investment (cost basis under 2 cents), but might adjust my target higher.
GemVest has entered into an exclusive and perpetual agreement with Peter Voutsas for his services to develop and manage this business. All purchase and resale business by Peter Marco Jewelers will now be done under the GemVest name. We expect that the proof of concept and a corresponding codification of operating procedures and business practices will have been accomplished within the first six months of operations. Several highly visible appearances of Peter Marco jewelry in conjunction with the entertainment industry will be utilized as well to further enhance the branding and establish Peter as a celebrity to facilitate our rollout into other world center cities.
Increasingly, Peter has taken advantage of his retail store’s location and his reputation for integrity, fairness, and expertise by becoming “the place to go” to dispose of precious diamonds and other investment grade stones and heirloom jewelry for those desiring to convert highly valued holdings into cash. Because of the high worth of some of these items, some valued in excess of $35 million, Peter has, until now, relied on taking such goods on a consignment basis and earning a modest consignment fee. This has restricted his earnings while impairing his serving his customers to the fullest extent because of their preference for immediate cash. GemVest plans to purchase such items outright, often at very discounted prices, providing the seller immediate cash and providing the Company with gross margins typically anywhere between 30%-70%.
Some of the key factors that will help GemVest expand its operations include: Timely access to capital and debt financing sufficient to support increasing capital requirements in order for GemVest to avail itself of expansion opportunities and respond to new business opportunities. We anticipate linking with an international investment bank that wishes to help develop a securitized asset backed portfolio of precious stones.
To select an esteemed investment bank partner interested in pursuing the regulatory filing and sale of bundled $100MM investment grade diamonds to high net worth investors
GemVest will target only in the upper echelon of high quality diamonds, with an average sale expected to be in the hundreds of thousands of dollars. The Company’s initial target is the top 25% of the diamond market, including the top ten percent of upper-echelon buyers. First year sales volume is targeted at $30-60 million.
Wound care products...interview statements.....
According to Tuesday's (1/29/2013) blog post on the Vitro Biopharma website, the company is developing a wound healing product using mesenchymal stem cells.....
......Vitro Biopharma is now developing a MSC-based wound healing product and plans animal testing of this product in the near future.
Another current objective is applying stem cell technology to advance regenerative medicine. I think we should be close to completion of the development of our initial products for use in accelerated wound healing.
We have other collaborators that are very important to us too. Dr. Jim Posillico is a long-term colleague of mine. He is the licensee of our FSH technology & products. He is also involved in some new activities that complement our regenerative medicine initiative. He is licensing in technology that would provide very critical drug delivery and cell delivery methodologies for especially wound care products that we have in our pipeline as well as other delivery processes.
maronti1...acquisition terms.....
what they actually paid for that this company in dollars value?
Section 3.2 Clawback. If the Company’s EBITDA (as defined in GAAP) is not at least $750,000 for the fiscal year ended December 31, 2014, then the Seller shall return to Purchaser 1 million shares of the Purchaser’s Common Stock for each $10,000 increment by which EBITDA is less than $750,000.
New GEPC-related websites.....
I'm still expecting to see higher prices here once the press releases and/or promotional activities start. I was looking to get a minimum of a 5-bagger on this investment (cost basis under 2 cents), but might adjust my target higher.
GEPC is somewhat interesting right now because management doesn't appear to be completely following their usual method. Normally, they like to start the stock out at a much higher price (usually in the dollars), and then the share price deteriorates as the dilution and fundamental adjustments kick in. So unless they are planning to do a reverse split in the near-term there might be an interesting window of opportunity in the next 1-3 months in which the stock might get pushed higher from this 5-cent area.
From the 8-K and the new websites, it looks like Peter Voutsas (from Peter Marco Jewelry) will be the prominent figure on the new business.......
GemVest, a division of GEPCO, Ltd., actively sources large inventories of high grade polished diamonds for resale through auctions, diamond investors, retailers, other diamond distributors, and jewelry manufacturers throughout the United States. GemVest's sourcing of diamonds is headed by Peter Voutsas, a 20 year diamond veteran and owner of Peter Marco Jewelry in Beverly Hills, CA. The GemVest concept is quite simple, sourcing and purchasing high quality investment grade diamonds at a discount and selling them at substantially higher prices.
GemVest's operations consist of importing and sourcing wholesale lots of diamonds of investment grade, shape, and color. The business, in turn, then sources jewelry manufacturers, other diamond distributors, and jewelers that readily purchase inventories directly from the GemVest. Mr. Voutsas is currently working with a number of market suppliers including diamond mines and the South African DeBeers diamond cartel. Management anticipates that each wholesale diamond order will carry a ticket value of $300,000 to $5,000,000 and gross margins in excess 30%. The business will hire certified gemologists to ensure that each diamond is properly categorized, given a proper serial number, and that the proper documentation for each diamond (or wholesale diamond lots) is prepared for the buying customer. GemVest maintains a highly secure facility from which to hold, polish, package, and distribute its diamond inventories.
db7...proposed merger, debt reduction.....
As currently contemplated, and based upon the current financial conditions of both parties to the Merger, the consideration for the Merger would consist of Vitro issuing 4.0 million shares of common stock and paying an additional $250,000 on terms yet to be determined. The Letter of Intent also contemplates the conversion of accrued debt to Vitro Biopharma's president into 1.0 million shares of common stock and other balance sheet restructuring.
VKIN...floorless convertible financing.....
VKIN continues to have some intriguing/significant potential upside, which is why I still hold my full position here (see posts below). However, there is a real possibility that much of that potential may never get realized as long as the current management/directors remain in place.
The inability/unwillingness of Simeo/management to provide information and clarification on a number of matters here has been extremely disappointing to me, to put it mildly.
Regarding the involvement of this latest awareness/promotion firm: IMO, if there is going to be a significant pick up in business activity at VKIN, the $20K worth of stock given to this firm would have been better spent toward hiring a well-established, dedicated investor relations firm that is capable of creating well-worded, detailed, coherent, accurate press releases and related IR material. But any IR firm worth its salt is going to request the same type of information/clarifications that I have been seeking, and as noted above management doesn't seem interested in doing that. So I guess this is a moot point.
On May 21, 2013, the Company issued a $58,000 8% convertible note with a term expiring on February 28, 2014 (the “Maturity Date”). The principal amount of the note and interest is payable on the maturity date. The note is convertible into common stock beginning 180 days after the issuance date, at the holder’s option, at a 58% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the note in full, the Company is required to pay off all principal, interest and any other amounts owing multiplied by (i) 130% if prepaid during the period commencing on the closing date through 60 days thereafter, (ii) 135% if prepaid 61 days following the closing through 90 days following the closing, (iii) 140% if prepaid 91 days following the closing through 120 days following the closing, (iv) 150% if prepaid 121 days following the closing through 180 days following the closing, and (v) 175% if prepaid 181 days following the closing through the maturity date. The terms of the convertible note provide for certain redemption features which include features indexed to equity risks. In the event of default, the amount of principal and interest not paid when due bear interest at the rate of 22% per annum and the note becomes immediately due and payable.
Vitropin commercialization statement....
The first quarter report also reiterates VODG's expectation that the company's fertility drug (Vitropin) will experience commercialization during 2013. That would roughly fit into the 2.5-year (March 2011 - September 2013) revenue-production time frame that VODG and James Posillico had settled on in the license agreement.
I had assumed/guessed that commercialization would probably require more time, but since CEO Musick doesn't seem to be backing away or hedging on the statement, it would seem that Posillico must be fairly confident that he can begin commercialization this year.
It should be very interesting to see what the reaction from the pump/promotion types of websites and/or momentum groups/players will be. Depending on what VODG will be permitted to say/PR about the commercialization, the "optics" of a low-priced biotech getting a drug commercialized by someone like James Posillico will probably raise a few eyebrows.
Posillico knows the fertility-related market about as well as anybody out there (and has extensive experience/contacts in the venture capital and financing areas), so outside of VODG licensing its drug technology to one of the existing biotechs/biopharmas in the space VODG probably couldn't ask for a better licensee than Posillico.
Traderfan...reason for the split.....
What brings me to whole different question. Why does a company with 23 million shares out want to do a RS 10-1??
TallTrader...reverse split not completed.....
So your opinion is the same as mine, that the reverse split has not been completed. Correct?
TGFN...reverse split controversy.....
Whoever put together the 10-K filing for TGFN really made a bit of mess by forgetting that the 1:10 reverse split hasn't occurred yet, so the numbers/info in the filing are pretty confusing.
BFNH(.0255)...established a position.....
Picked up a few shares of BFNH at 3 cents for a speculative position, just in case any OTC or SEC filings appear and trigger some buying interest.
Following the resignation of officers, appointment of a new CEO and reinstatement of the stock in March, I am assuming that BFNH is currently in shell status. But it certainly appears to me that some corporate event/action may be approaching at some point "relatively soon".
It has gone largely unnoticed, but on July 29 BFNH's corporate officer list on Nevada was updated to include Richard Kaiser as Secretary. It would seem highly unusual for a shell to hire/appoint Kaiser (Yes International, investor relations firm) as Secretary unless there are plans to make filings and/or press releases.......
http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=tfLZXJ05SvnEfwCvfk2lQw%253d%253d&nt7=0
db7...management/director changes.....
Potse, see the 8k? good to see some signs of life..
Mr. Jingwei (John) Huang, age 37, has been affiliated with KPMG from July 2000 to the present, most recently as a Senior Manager. In such capacity his responsibilities included planning and supervising the audits of various private and public companies, including the audits for various listed companies and companies in the process of completing initial public offerings. As a Senior Manager, Mr. Wang also had responsibility for client solicitation and management. Mr. Huang received a degree in Industrial and Civil Engineering from South China University of Technology in 1999 and an MBA from South China University of Technology in 2000.
Mr. Bo (Richard) Jiang, age 34, served as a Director of Vastsea Consultants from March 2011 to June 2013. In such position he was responsible for human resource outsourcing and headhunting services. He served as a manager of a 15 person team with responsibility for the achievement of targeted goals. Prior to that, from February 2010 until March 2011, Mr. Jiang was Executive Assistant to the CEO of AB Securities. In this position Mr. Jiang was in regular communication with the China Insurance Regulatory Commission, was responsible for coordinating the Process Optimization Project with McKinsey and ensuring that the Project was properly implemented throughout the organization. From March 2007 through February 2010 Mr. Jiang was a Regional Manager for Aramark, a leader in professional services, food services and facilities management for institutions throughout the world. In 2005 Mr. Jiang received his undergraduate degree from France Universitaire d’Angers from which he also received an advanced degree in Economic Management in 2007.
Management/Director positions added at Nevada......
It hasn't been disclosed in any SEC filing yet, but it is interesting to note that when CDBH filed its 2013 Annual List with Nevada on August 27 (19 days ago) there were 3 management/director positions added.
I'll be curious to see the background on the "Zhang Li" that is identified as being one of the new additions. I remember that name from the days when Chardan Capital was heavily involved with China SPACs (Special Purpose Aquisition Company). It would be a bit interesting if this particular Zhang Li is the same person who used to be a partner at Chardan Capital and held management/director positions on some of Chardan's SPACs.
Teng Jianfang -- Secretary
Liang Lifang -- Director/Manager of Administration
Zhang Li -- Director/CFO
http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=OdNv1UJOpnPjO7j24XQ9Tg%253d%253d&nt7=0
http://www.chardancapitalmarkets.com/
TEEE(.09)...2-part reverse merger.....
5.85M shares outstanding
$526K market cap
A 1:14.62 reverse split is expected in the next week or so.
Picked up a few more shares of the TEEE shell. All significant debt/liabilities appear to have been resolved now, with conversions into common stock generally in the 4-7 cent area (including shares issued to the shell's CEO, who will remain a Director with the new company).
The valuation of the shell under the 10-cent area still seems reasonable to me prior to the entry into a RM deal. Although there is quite a bit of risk involved here since I don't know what the financials and balance sheet of the RM target(s) look like, or what the final share structure will look like, I think there is a chance this stock might become an interesting low float and/or momentum play at some point after the reverse merger. Following the reverse split and the first part of the RM transaction, it appears that the tradeable float on this stock could be as low as 250K for awhile.
RM part one: 1:14.62 reverse split, name change to "Fuse Medical", and issue 3.6M shares to acquire PharmHouse Pharmacy. Total shares outstanding will be 4M.
Craig Longhurst, owner of PharmHouse Pharmacy, will control 2.9M shares of the company at that point.
RM part two: acquisition of Fuse Medical, LLC.
Details of that proposed transaction have not be disclosed yet, but according to the filings (SC 14F1) Craig Longhurst is expected to distribute some of his shares as part of the deal......
Mr. Longhurst has agreed to distribute a portion of the shares issued to him in connection with a proposed acquisition of Fuse Medical, LLC.
HemoGenix..$500K financing, Rockies Venture Club.....
I don't see it as being anything specifically related to any possible RM with VODG. I just find it a bit interesting because it seems to be somewhat out of the ordinary from the time I have followed/monitored the company.
Early last year HemoGenix introduced a bunch of new assay platforms (some of which include VODG's cell culture media), hired at least 5 sales/marketing people just prior to the introduction of those new products, and HemoGenix CEO Ivan Rich increased his presence on the conference circuit in 2012 with some high-profile presentations and speaking opportunities. So with HemoGenix seemingly more interested in attracting outside investment it might be an indication that HemoGenix sees a need for more growth/expansion capital.
Neuromics and HemoGenix are probably the most likely/obvious candidates for some type of merger with VODG because James Musick has more or less hinted at that possibility in his press releases and filings during the time VODG has been associated with those companies.
But there are no shortage of potential RM or acquisition candidates out there (many right there in the Denver/Colorado area) if Musick decides he wants to make some type of strategic move either in the biotech/medical sector, or take the operating company private and enter into a RM with a company outside of that particular sector if a better/irresistible opportunity arose.
Due to difficult market conditions traditional IPOs are pretty much out of the question for anything except the largest, most high-profile private companies now and for the foreseeable future. And although the federal government (and SEC) continues to try and strangle the life out of smaller companies and reverse merger opportunities, the fact remains that the RM route is about the only realistic exit opportunity remaining for owners/investors to try to maximize their holdings/investments.
I noticed back in June 2012, Clifford Neuman (VODG's lawyer and the President of GBCS) decided to begin the process of divesting the casino operations out of GBCS. Christopher Brogdon (Chief Acquisition Officer and Vice Chairman of AdCare Healthcare Systems -- NYSE: ADK) is using the GBCS shell for his new healthcare REIT company. It is a bit surprising that someone like Brogdon decided not to use an already clean, ready-to-go shell, but it just goes to show you that just about anything can happen in the RM world if you know or have connections to the right people.
Just posted bio science firm investment deal info for @Hemogenix to Gust.com
Already have 1st interested investment firm ready for due diligence for @Hemogenix Wow.
Presented @Hemogenix at @RockiesVenture 's Summer Pitch Fest last night. Seeking $500K as 1st round for pre-acquisition growth stage
FlashCashDirect website......
Redify's primary products are currently the SportsCast line of apps and its soon-to-be-released lead generation business for the financial sector.
FlashCashDirect is a free, no obligation financial marketing service, matching prospective borrowers with prospective lenders for short-term loans......
...... FlashCashDirect is operated by TGFIN Holdings Inc. You can send mail to us c/o TGFIN Holdings, Suite B, 101 North Main Street, Smithfield, UT 84334
EX_HI...change in business direction.....
I'm still holding a position in EX_HI, established prior to the previous reverse merger a few years ago. I didn't think that RM (a Japanese wedding/travel service and products type of company) would really develop into anything significant or attract investor interest, so I decided to keep the shares and wait for the next RM or something. This will probably be the last RM or business change I stick through on this particular stock, as most likely significant dilution and/or significant changes in the float will eventually occur now.
It looks like EX_HI unwound the RM earlier this year and has now changed its business direction to that of a US-based medical equipment supplier. The recent flurry of filings by the company still hasn't provided sufficient information on the terms of the debt it has on the books, or what the share structure will ultimately look like.
The outstanding share count at April 30 was 20M and a float around 2.2+M. For the entire time I have followed this stock, it has generally traded as if it has a pretty low float, and by the looks of today's trading that continues to be the case. If the stock attracts some momentum/promo interest before significant dilution sets in, things might get a little interesting.
http://exlitesmedical.com/
Ares Song's LinkedIn page updated.....
Recently, the name "Ares Song" started showing up on Murphy Liu's LinkedIn page. Song is a mining/metals consultant in China, and his LinkedIn page has provided some interesting information on what Murphy Liu is currently involved in.
Ares Song
Executive Director at Golden Resource
Chile Mining & Metals
Ares Song's Experience
Executive Director
Golden Resource
May 2013– Present (3 months)
Consultant
Self-employed
June 2009– April 2013 (3 years 11 months)
Financial Planning, Investment Strategy, Project Assessment, Team Management.
Ares Song's Projects
Chile Mining
May 2013 to Present
Team Members: Ares Song, Murphy Liu
Copper, Gold, Diatomite, Lithium and etc..
Liu's LinkedIn page updated....SGBL trades higher.....
Recently, the name "Ares Song" started showing up on Murphy Liu's LinkedIn page. Song is a mining/metals consultant in China, and his LinkedIn page has provided some interesting information on what Murphy Liu is currently involved in.
murphy Liu
president at golden resource (chile) mining S.A
West Covina, California (Greater Los Angeles Area) Mining & Metals
murphy Liu's Experience
president
golden resource (chile) mining S.A
2013– Present (less than a year)
personal banker / loan officer
bank of america
Public Company; 10,001+ employees; BAC; Banking industry
November 2004– June 2010 (5 years 8 months)California